Manufacturer of Controlled Substances; Notice of Registration; Cambrex Charles City, Inc., 70189-70190 [2012-28499]
Download as PDF
<![CDATA[
70189
Federal Register / Vol. 77, No. 226 / Friday, November 23, 2012 / Notices
DEPARTMENT OF JUSTICE
Drug
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Registration;
Cayman Chemical Company
By Notice dated July 30, 2012, and
published in the Federal Register on
August 7, 2012, 77 FR 47115, Cayman
Chemical Company, 1180 East Ellsworth
Road, Ann Arbor, Michigan 48108,
made application by renewal to the
Drug Enforcement Administration
(DEA) to be registered as a bulk
manufacturer of the following basic
classes of controlled substances:
mstockstill on DSK4VPTVN1PROD with NOTICES
Drug
Schedule
Cathinone (1235) ..........................
Methcathinone (1237) ..................
4-Methyl-N-methylcathinone
(1248).
N-Ethylamphetamine (1475) ........
N,N-Dimethylamphetamine (1480)
Aminorex (1585) ...........................
4-Methylaminorex (cis isomer)
(1590).
Gamma
Hydroxybutyric
Acid
(2010).
1-Pentyl-3-(1-naphthoyl)
indole
(7118).
1-Butyl-3-(1-naphthoyl)
indole
(7173).
1-[2-(4-Morpholinyl)ethyl]-3-(1naphthoyl) indole (7200).
Alpha-ethyltryptamine (7249) .......
5-(1,1-Dimethylheptyl)-2-[(1R,3S)3-hydroxycyclohexyl]-phenol
(7297).
5-(1,1-Dimethyloctyl)-2-[(1R,3S)3-hydroxycyclohexyl]-phenol
(7298).
Lysergic acid diethylamide (7315)
2,5-Dimethoxy-4-(n)propylthiophenethylamine
(7348).
Marihuana (7360) .........................
Tetrahydrocannabinols (7370) .....
Mescaline (7381) ..........................
3,4,5-Trimethoxyamphetamine
(7390).
4-Bromo-2,5dimethoxyamphetamine (7391).
4-Bromo-2,5dimethoxyphenethylamine
(7392).
4-Methyl-2,5dimethoxyamphetamine (7395).
2,5-Dimethoxyamphetamine
(7396).
2,5-Dimethoxy-4ethylamphetamine (7399).
3,4-Methylenedioxyamphetamine
(7400).
5-Methoxy-3,4methylenedioxyamphetamine
(7401).
N-Hydroxy-3,4methylenedioxyamphetamine
(7402).
3,4-Methylenedioxy-Nethylamphetamine (7404).
VerDate Mar<15>2010
17:49 Nov 21, 2012
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
3,4Methylenedioxymethamphetamine (7405).
4-Methoxyamphetamine (7411) ...
5-Methoxy-N-Ndimethyltryptamine (7431).
Alpha-methyltryptamine (7432) ....
Bufotenine (7433) .........................
Diethyltryptamine (7434) ..............
Dimethyltryptamine (7435) ...........
Psilocybin (7437) ..........................
Psilocyn (7438) .............................
5-Methoxy-N-Ndiisopropyltryptamine (7439).
N-Benzylpiperazine (7493) ...........
3,4-Methylenedioxypyrovalerone
(7535).
3,4-Methylenedioxy-Nmethylcathinone (7540).
Amphetamine (1100) ....................
Methamphetamine (1105) ............
Lisdexamfetamine (1205) .............
I
I
[FR Doc. 2012–28500 Filed 11–21–12; 8:45 am]
I
I
I
I
I
I
I
I
I
I
II
II
II
The company plans to manufacture
small quantities of marihuana
derivatives for research purposes. In
reference to drug code 7360
(Marihuana), the company plans to bulk
manufacture cannabidiol. In reference to
drug code 7370
(Tetrahydrocannabinols), the company
will manufacture a synthetic THC. No
other activity for this drug code is
authorized for this registration.
The company plans to manufacture
the remaining listed controlled
substances to supply these materials to
the research and forensics community
for drug testing and analysis.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of
Cayman Chemical Company to
manufacture the listed basic classes of
controlled substances is consistent with
the public interest at this time. DEA has
investigated Cayman Chemical
Company to ensure that the company’s
registration is consistent with the public
interest. The investigation has included
inspection and testing of the company’s
physical security systems, verification
of the company’s compliance with state
and local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C.
823(a), and in accordance with 21 CFR
1301.33, the above named company is
granted registration as a bulk
manufacturer of the basic classes of
controlled substances listed.
I
Jkt 229001
I
Dated: November 14, 2012.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
Schedule
PO 00000
Frm 00054
Fmt 4703
Sfmt 4703
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Registration;
Cambrex Charles City, Inc.
By Notice dated July 17, 2012 and
published in the Federal Register on
July 26, 2012, 77 FR 43863, Cambrex
Charles City, Inc., 1205 11th Street,
Charles City, Iowa 50616, made
application by renewal to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
the following basic classes of controlled
substances:
Drug
Gamma
Hydroxybutyric
Acid
(2010).
Amphetamine (1100) ....................
Lisdexamfetamine (1205) .............
Methylphenidate (1724) ................
4-Anilino-N-phenethyl-4-piperidine
(ANPP) (8333).
Phenylacetone (8501) ..................
Cocaine (9041) .............................
Codeine (9050) .............................
Oxycodone (9143) ........................
Hydromorphone (9150) ................
Hydrocodone (9193) .....................
Methadone (9250) ........................
Dextropropoxyphene, bulk (nondosage forms) (9273).
Morphine (9300) ...........................
Oripavine (9330) ...........................
Thebaine (9333) ...........................
Opium, raw (9600) .......................
Opium extracts (9610) ..................
Opium fluid extract (9620) ............
Opium tincture (9630) ..................
Opium, powdered (9639) .............
Opium, granulated (9640) ............
Oxymorphone (9652) ...................
Noroxymorphone (9668) ..............
Poppy Straw Concentrate (9670)
Alfentanil (9737) ...........................
Remifentanil (9739) ......................
Sufentanil (9740) ..........................
Fentanyl (9801) ............................
Schedule
I
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
The company plans to manufacture
the listed controlled substances in bulk
for sale to its customers, for dosage form
development, for clinical trials, and for
use in stability qualification studies.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a), and
E:\FR\FM\23NON1.SGM
23NON1
70190
Federal Register / Vol. 77, No. 226 / Friday, November 23, 2012 / Notices
determined that the registration of
Cambrex Charles City, Inc., to
manufacture the listed basic classes of
controlled substances is consistent with
the public interest at this time. DEA has
investigated Cambrex Charles City, Inc.,
to ensure that the company’s
registration is consistent with the public
interest. The investigation has included
inspection and testing of the company’s
physical security systems, verification
of the company’s compliance with state
and local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C.
823(a), and in accordance with 21 CFR
1301.33, the above named company is
granted registration as a bulk
manufacturer of the basic classes of
controlled substances listed.
Dated: November 14, 2012.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2012–28499 Filed 11–21–12; 8:45 am]
BILLING CODE 4410–09–P
LEGAL SERVICES CORPORATION
Sunshine Act Meetings; Notice
The Legal Services
Corporation’s Board of Directors will
meet telephonically on November 29,
2012. The meeting will commence at
5:00 p.m., Eastern Standard Time, and
will continue until the conclusion of the
Board’s agenda.
LOCATION: F. William McCalpin
Conference Center, Legal Services
Corporation Headquarters, 3333 K Street
NW., Washington DC 20007.
PUBLIC OBSERVATION: Members of the
public who are unable to attend in
person but wish to listen to the public
proceedings may do so by following the
telephone call-in directions provided
below but are asked to keep their
telephones muted to eliminate
background noises. To avoid disrupting
the meeting, please refrain from placing
the call on hold if doing so will trigger
recorded music or other sound. From
time to time, the presiding Chair may
solicit comments from the public.
CALL-IN DIRECTIONS FOR OPEN SESSIONS:
• Call toll-free number: 1–866–451–
4981;
• When prompted, enter the
following numeric pass code:
5907707348;
• When connected to the call, please
immediately ‘‘MUTE’’ your telephone.
STATUS OF MEETING: Open.
MATTERS TO BE CONSIDERED:
mstockstill on DSK4VPTVN1PROD with NOTICES
DATE AND TIME:
VerDate Mar<15>2010
17:03 Nov 21, 2012
Jkt 229001
1. Approval of Agenda.
2. Approval of minutes of the Board’s
meeting of October 1–2, 2012.
3. Consider and act on the Board of
Directors’ transmittal to accompany the
Inspector General’s Semiannual Report
to Congress for the period of April 1,
2012 through September 30, 2012.
4. Report on legal services needs and
activities relating to Hurricane Sandy.
5. Public comment.
6. Consider and act on other business.
7. Consider and act on motion to
adjourn the meeting.
*
*
*
*
*
CONTACT PERSON FOR INFORMATION:
Katherine Ward, Executive Assistant to
the Vice President & General Counsel, at
(202) 295–1500. Questions may be sent
by electronic mail to
FR_NOTICE_QUESTIONS@lsc.gov.
NON-CONFIDENTIAL MEETING MATERIALS:
Non-confidential meeting materials will
be made available in electronic format at
least 24 hours in advance of the meeting
on the LSC Web site, at https://www.lsc.
gov/board-directors/meetings/boardmeeting-notices/non-confidentialmaterials-be-considered-open-session.
ACCESSIBILITY: LSC complies with the
American’s with Disabilities Act and
Section 504 of the 1973 Rehabilitation
Act. Upon request, meeting notices and
materials will be made available in
alternative formats to accommodate
individuals with disabilities.
Individuals who need other
accommodations due to disability in
order to attend the meeting in person or
telephonically should contact Katherine
Ward, at (202) 295–1500 or
FR_NOTICE_QUESTIONS@lsc.gov, at
least 2 business days in advance of the
meeting. If a request is made without
advance notice, LSC will make every
effort to accommodate the request but
cannot guarantee that all requests can be
fulfilled.
Dated: November 20, 2012.
Victor M. Fortuno,
Vice President and General Counsel.
[FR Doc. 2012–28599 Filed 11–20–12; 4:15 pm]
BILLING CODE 7050–01–P
NUCLEAR REGULATORY
COMMISSION
[Docket No. NRC–2012–0149]
Agency Information Collection
Activities: Submission for the Office of
Management and Budget (OMB)
Review; Comment Request
Nuclear Regulatory
Commission.
AGENCY:
PO 00000
Frm 00055
Fmt 4703
Sfmt 4703
Notice of the OMB review of
information collection and solicitation
of public comment.
ACTION:
The U.S. Nuclear Regulatory
Commission (NRC) has recently
submitted to OMB for review the
following proposal for the collection of
information under the provisions of the
Paperwork Reduction Act of 1995 (44
U.S.C. Chapter 35). The NRC hereby
informs potential respondents that an
agency may not conduct or sponsor, and
that a person is not required to respond
to, a collection of information unless it
displays a currently valid OMB control
number. The NRC published a Federal
Register notice with a 60-day comment
period on this information collection on
August 1, 2012 (77 FR 45697).
1. Type of submission, new, revision,
or extension: Extension.
2. The title of the information
collection: Part 60 of Title 10 of the
Code of Federal Regulations (10 CFR),
‘‘Disposal of High-Level Radioactive
Wastes in Geologic Repositories.’’
3. Current OMB approval number:
3150–0127.
4. The form number if applicable: N/
A.
5. How often the collection is
required: The information need only be
submitted one time.
6. Who will be required or asked to
report: State or Indian tribes, or their
representatives, requesting consultation
with the NRC staff regarding review of
a potential high-level radioactive waste
geologic repository site, or wishing to
participate in a license application
review for a potential geologic
repository (other than a potential
geologic repository site at Yucca
Mountain, Nevada, which is regulated
under 10 CFR part 63).
7. An estimate of the number of
annual responses: 1; however, none are
expected in the next 3 years.
8. The estimated number of annual
respondents: 1; however, none are
expected in the next 3 years.
9. An estimate of the total number of
hours needed annually to complete the
requirement or request: 1 hour;
however, none are expected in the next
3 years.
10. Abstract: Part 60 requires States
and Indian tribes to submit certain
information to the NRC if they request
consultation with the NRC staff
concerning the review of a potential
repository site, or wish to participate in
a license application review for a
potential repository (other than the
Yucca Mountain, Nevada site, which is
regulated under 10 CFR part 63).
Representatives of States or Indian
tribes must submit a statement of their
SUMMARY:
E:\FR\FM\23NON1.SGM
23NON1
]]>Agencies
[Federal Register Volume 77, Number 226 (Friday, November 23, 2012)]
[Notices]
[Pages 70189-70190]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2012-28499]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of Registration;
Cambrex Charles City, Inc.
By Notice dated July 17, 2012 and published in the Federal Register
on July 26, 2012, 77 FR 43863, Cambrex Charles City, Inc., 1205 11th
Street, Charles City, Iowa 50616, made application by renewal to the
Drug Enforcement Administration (DEA) to be registered as a bulk
manufacturer of the following basic classes of controlled substances:
------------------------------------------------------------------------
Drug Schedule
------------------------------------------------------------------------
Gamma Hydroxybutyric Acid (2010)........... I
Amphetamine (1100)......................... II
Lisdexamfetamine (1205).................... II
Methylphenidate (1724)..................... II
4-Anilino-N-phenethyl-4-piperidine (ANPP) II
(8333).
Phenylacetone (8501)....................... II
Cocaine (9041)............................. II
Codeine (9050)............................. II
Oxycodone (9143)........................... II
Hydromorphone (9150)....................... II
Hydrocodone (9193)......................... II
Methadone (9250)........................... II
Dextropropoxyphene, bulk (non-dosage forms) II
(9273).
Morphine (9300)............................ II
Oripavine (9330)........................... II
Thebaine (9333)............................ II
Opium, raw (9600).......................... II
Opium extracts (9610)...................... II
Opium fluid extract (9620)................. II
Opium tincture (9630)...................... II
Opium, powdered (9639)..................... II
Opium, granulated (9640)................... II
Oxymorphone (9652)......................... II
Noroxymorphone (9668)...................... II
Poppy Straw Concentrate (9670)............. II
Alfentanil (9737).......................... II
Remifentanil (9739)........................ II
Sufentanil (9740).......................... II
Fentanyl (9801)............................ II
------------------------------------------------------------------------
The company plans to manufacture the listed controlled substances
in bulk for sale to its customers, for dosage form development, for
clinical trials, and for use in stability qualification studies.
No comments or objections have been received. DEA has considered
the factors in 21 U.S.C. 823(a), and
[[Page 70190]]
determined that the registration of Cambrex Charles City, Inc., to
manufacture the listed basic classes of controlled substances is
consistent with the public interest at this time. DEA has investigated
Cambrex Charles City, Inc., to ensure that the company's registration
is consistent with the public interest. The investigation has included
inspection and testing of the company's physical security systems,
verification of the company's compliance with state and local laws, and
a review of the company's background and history.
Therefore, pursuant to 21 U.S.C. 823(a), and in accordance with 21
CFR 1301.33, the above named company is granted registration as a bulk
manufacturer of the basic classes of controlled substances listed.
Dated: November 14, 2012.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. 2012-28499 Filed 11-21-12; 8:45 am]
BILLING CODE 4410-09-P
